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Turbulent flow chromatography coupled to
tandem mass spectrometry (TFC-LC-MS/MS)
Principal Component AnalysisPerfluoroalkyl substances (PFASs) are environmental pollutants with an important bioaccumulation poten-
tial. However, their metabolism and distribution in humans are not well studied. In this study, the concentra-
tions of 21 PFASs were analyzed in 99 samples of autopsy tissues (brain, liver, lung, bone, and kidney) from
subjects who had been living in Tarragona (Catalonia, Spain). The samples were analyzed by solvent extrac-
tion and online purification by turbulent flow and liquid chromatography coupled to tandemmass spectrom-
etry. The occurrence of PFASs was confirmed in all human tissues. Although PFASs accumulation followed
particular trends depending on the specific tissue, some similarities were found. In kidney and lung,
perfluorobutanoic acid was the most frequent compound, and at highest concentrations (median values:
263 and 807 ng/g in kidney and lung, respectively). In liver and brain, perfluorohexanoic acid showed the
maximum levels (median: 68.3 and 141 ng/g, respectively), while perfluorooctanoic acid was the most con-
tributively in bone (median: 20.9 ng/g). Lung tissues accumulated the highest concentration of PFASs.
However, perfluorooctane sulfonic acid and perfluorooctanoic acid were more prevalent in liver and bone,
respectively. To the best of our knowledge, the accumulation of different PFASs in samples of various
human tissues from the same subjects is here reported for the very first time. The current results may be
of high importance for the validation of physiologically based pharmacokinetic models, which are being
developed for humans. However, further studies on the distribution of the same compounds in the human
body are still required.
© 2013 Elsevier Ltd. All rights reserved.1. Introduction
Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are a large
group of surface-active organic compounds. Because of their chemical
and thermal stability, as well as their hydrophobic and lipophobic na-
ture, they have been used for over 50 years in a number of industrial
and commercial applications (Zhao et al., 2012). PFASs are highly resis-
tant to breakdown. Therefore, they are persistent in the environment,
being able to accumulate in living organisms and biomagnified through
the trophicweb (Loi et al., 2011; Powley et al., 2008).Moreover, there is
a growing concern related to their potentially harmful effects on human
health (Vieira et al., 2013). Due to these reasons, the U.S. industry un-
dertook voluntary actions to phase out production of perfluorooctane
sulfonic acid (PFOS) between 2000 and 2002, and in 2007 the United
States Environmental Protection Agency (US EPA) published the Signif-
icant New Use Rules (SNURs) to restrict the production of PFOS and
related substances (Lindstrom et al., 2011). Moreover, in 2006, the
major PFAS producers committed the Stewardship Program to phase
out the global emissions and products containing perfluorooctanoicrights reserved.acid (PFOA) for 2015. Despite these measures, hundreds of other differ-
ent PFASs are currently being produced and used. Thus, although the
production of PFOA is being phased out by the companies participating
in the Voluntary Stewardship Program, environmental contamination
and human exposure from PFOA and higher homologue chemicals
(e.g. PFNA, PFDA, etc.) are anticipated to continue for the foreseeable fu-
ture due to a number of reasons: its persistence, their formation from
precursor compounds, and the potential for continued production by
othermanufacturers in the U.S. and/or overseas (Lindstromet al., 2011).
In 2008, the European Food SafetyAuthority (EFSA, 2008) established
a series of Tolerable Daily Intakes (TDIs) values for PFOS and PFOA at 150
and 1500 ng/kg/day, respectively. PFOS was subsequently included as a
persistent organic pollutant (POP) under the Stockholm Convention
(UNEP 2010). In 2009, the US EPA Office of Water established the provi-
sional health advisory values for PFOS and PFOA at 200 and 400 ng/L,
respectively. It must be highlighted that, although TDIs and the water
provisional health advisory were calculated in different basis, in both
cases short-term exposure was considered as the relevant period of
exposure. This was consistent with PFOA and PFOS toxicity data, which
in turn rely upon subchronic exposure experimental values. However,
long-term exposures must be considered for the accurate assessment
of their potential risk on human health, taking into account that their
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(Domingo et al., 2012a,b; Ericson Jogsten et al., 2012; Ericson et al.,
2008, 2009; Post et al., 2009, 2012).
PFASs have been related to different toxicological effects on mam-
mals. In mice, the neonatal exposure to PFOS and PFOA has been linked
up to changes in proteins of importance for the neuronal growth and
synaptogenesis in the brain developing (Johansson et al., 2009), as
well as with neurobehavioral defects and changes in the cholinergic
system (Johansson et al., 2008). In addition, perfluorohexanesulphonate
(PFHxS) has been related to irreversible neurotoxic effects in neonatal
mice, showing a similar behavior to that of other POPs, such as
polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers
(PBDEs) and bisphenol A (Viberg et al., 2013). A recent study in human
suggested that higher PFOA serum levels might be associated with testic-
ular, kidney, prostate, and ovarian cancers, and non-Hodgkin lymphoma,
according to the concentrations of residents in 6 areaswith contaminated
drinking water supplies (Vieira et al., 2013).
In the human body, the polar hydrophobic nature of fluorine-
containing compounds can lead to increased affinity for proteins (Jones
et al., 2003; Luebker et al., 2002; Vanden Heuvel et al., 1992; Weiss
et al., 2009). A number of PFASs have been detected in human serum,
cord blood and breast milk (Domingo et al., 2012a; Ericson et al., 2007;
Fromme et al., 2010; Haug et al., 2009a,b; Llorca et al., 2010). As
other bioacumulative halogenated contaminants (e.g., polychlorinated
dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) and PCBs), PFASs can
have long persistence in the body. However, they do not tend to accumu-
late in fat tissue. According to outcomes of animal studies, PFOA and PFOS
aremostly excreted through the urine (Cui et al., 2010), but limited obser-
vations in humans suggest that only one-fifth of the total body clearance
is renal (Harada et al., 2005). The elimination half-life of PFOA in humans
was roughly estimated to be 3.5 years, while that of PFOS was approxi-
mately 4.8 years (Olsen et al., 2007), according to data from retired
workers. Post et al. (2012) recently reviewed studies reporting the elimi-
nation half-life values between 2.3 and 3.3 years, following an exposure
to contaminated drinking water (Post et al., 2012). Information about
sources, environmental fate and toxicokinetics of PFOS and PFOA is large-
ly available, while estimation values in the half-lives of PFBS, PFHxS and
PFBA (Chang et al., 2008; Lau et al., 2007). In contrast, data on most of
the PFASs currently in use, continues to be very limited. It has been hy-
pothesized that the possible harmful effects associated to PFASs accumu-
lation are of special concern during early stages of life (Maisonet et al.,
2012; Post et al., 2012; Schecter et al., 2012).However, their accumulation
anddistribution in the different human tissues are still poorly understood.
The potential accumulation of PFASs with different chain lengths is an
issue of great importance for exposure assessment and risk characteriza-
tion studies.Most current investigations onhuman accumulation have fo-
cused on the occurrence in blood and breast milk, while very few studies
have reported levels in other tissues. Kärrman et al. (2009) determined
the concentrations of six PFASs in liver samples collected post-mortem
in Spain.Mean concentrations of 27 and 1 ng/g of PFOS and PFOA, respec-
tively, were found. In turn, Maestri et al. (2006) found levels of 14 ng/g of
PFOS and3 ng/g of PFOA in apooled liver samples corresponding to seven
subjects from northern Italy, while Olsen et al. (2003) reported mean
PFOS and PFOA concentrations of 19 and 47 ng/g, respectively, in 30 sub-
jects fromUSA. Finally, Pirali et al. (2009) detected PFOA and PFOS in thy-
roid tissue (median levels: 2 and 5.3 ng/g, respectively), concluding that
those compounds are not actively concentrated in the thyroid.
Themain objectives of the present studywere the following: 1) to opti-
mize and validate an on-line analytical approach based on turbulent flow
chromatography coupled to tandem mass spectrometry (TFC-LC-MS/MS)
for determining PFASs in various human tissues; 2) to measure the levels
of 21 PFASs in these human tissues in order to elucidate their distribution
and accumulation in the human body. Themethod optimized for the tissue
analysis was carefully selected to accomplish the minimum sample size
requirements and to reduce samplemanipulation. The analytical proce-
dure was validated for different kinds of tissues, and applied for thedetermination of selected compounds in liver, lung, brain, bone, and
kidney samples collected post-mortem from 20 subjects. PFASs values
were correlated with the concentrations of some heavy metals
(unpublished results) in the same tissue samples, as well as with the
levels of PCDD/Fs in adipose tissue from 15 of the same individuals
(Nadal et al., 2009). To the best of our knowledge, these are the first
data reporting the accumulation of a notable number of PFASs in
human tissues, as well as comparing the body burden of these pollut-
ants with that of other environmental contaminants (metals and
PCDD/Fs).
2. Materials and methods
2.1. Chemicals and standards
Standard solutionswere purchased fromWellington Laboratories Inc.
(Guelph, ON, Canada). The standard analytes used in this study were:
i) PFAC-MXB [98% purity in methanol] containing perfluorobutanoic
acid (PFBA), perfluoropentanoic acid (PFPeA), perfluorohexanoic
acid (PFHxA), perfluoroheptanoic acid (PFHpA), perfluorooctanoic acid
(PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid
(PFDA), perfluoroundecanoic acid (PFUdA), perfluorododecanoic
acid (PFDoA), perfluorotridecanoic acid (PFTrA), perfluorotetradecanoic
acid (PFTeA, perfluorohexadecanoic acid (PFHxDA), perfluoroocta-
decanoic acid (PFODA), perfluorobutanesulphonate (PFBS), perfluoro-
hexanesulphonate (PFHxS), perfluorooctanesulphonate (PFOS) and
perflurodecanesulphonate (PFDS); ii) FTA [98% purity in isopropanol]
including perfluorohexyl ethanoic acid (FHEA), perfluorooctyl ethanoic
acid FOEA, and perfluorodecyl ethanoic acid FDEA; iii) perfluorooctane
sulfonamide (PFOSA) [98% pure in methanol]. Identification and
quantification were performed using the following internal standards:
i) MPFAC-MXA [>98%] containing [13C4]-perfluorobutanoic acid
(MPFBA (13C4)), ion [18O2]-perfluorohexanesulfonate (MPFHxS
(18O2)), [13C2]-perfluorohexanoic acid (MPFHxA (13C2)), ion [13C4]-
perfluorooctanesulfonate (MPFOS (13C4)), [13C4]-perfluorooctanoic acid
(MPFOA (13C4)), [13C5]-perfluorononanoic acid (MPFNA (13C5)), [13C2]-
perfluorododecanoic acid (MPFDoA (13C2)), [13C2]-perfluorodecanoic
acid (MPFDA (13C2)), [13C2]-perfluoroundecanoic acid (MPFUdA
(13C2)); ii) MFTA-MXA [>98%] [13C2]-perfluorohexylethanoic acid
(MFHEA(13C2)), [13C2]-perfluorooctylethanoic acid (MFOEA(13C2)),
[13C2]-perfluorodecylethanoic acid (MFDEA (13C2)) and iii) [13C8]-
perfluorooctanesulfonamide (MPFOSA (13C8)).
Water, methanol, acetonitrile, CHROMASOLV®Plus for HPLC
grade, ammonium acetate salt (AcNH4: MW, 77.08; 98%), and formic
acid (HFo) were obtained from Sigma-Aldrich (Steinheim, Germany).
To remove possible cross contamination, polypropylene (PP) insert
vials and inert taps were used.
2.2. Sampling and pre-treatment
Samples from liver, kidney, brain, lung, and bone (rib) were collect-
ed in 2008 from 20 subjects who had been living in different areas of
TarragonaCounty (Catalonia, Spain) at least for the last 10 years. Causes
of death were varied, including multiple trauma, subdural hematoma,
ischemic heart disease, accident or self-injury. Autopsies and extraction
of sampleswere carried out during the first 24 h after the time of death.
Additional data from the subjects, such as age (mean: 56; range: 28–83)
and smoking habits information, were collected (Table S1; Supporting
Information). Tissue samples were stored at −20 °C before analysis.
The study protocol was reviewed and approved by the Ethical Commit-
tee for Human Studies of the School of Medicine, Universitat Rovira i
Virgili, Reus/Tarragona, Spain.
Sample pre-treatmentwas based on a previously published protocol
(Llorca et al., 2010). Briefly, 1 g of each sample was weighed and trans-
ferred into a 15 mL PP tube. Then, 2 mL of water were added, and the
mixture was shaken. Homogenates were fortified with surrogate
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of 10 μg/L), being digested with 5 mL of sodium hydroxide (20 mM in
methanol) during 4 h at 125 rpm on an orbital shaker table at room
temperature. After digestion, samples were centrifuged at 4000 rpm,
and 20 μL of supernatant were directly injected into the turbulent
flow chromatography system.2.3. Analysis
A turbulent flow chromatograph Aria TLX-1 system (Thermo Fisher
Scientific, Franklin, MA, USA) comprised of a PAL auto sampler (CTC
Analytics, Zwingen, Switzerland), two mixing binary pumps (eluting
pump and loading pump), and a three-valve switching device unit
with six-port valve. The entire systemwas controlled via Aria software,
version 1.6. The on-line enrichment was achieved using a Hypersil
GOLD aQ column (2.1 × 20 mm, 12 μmparticle size from Thermo Fisher
Scientific, Franklin, MA, USA). The analytical column used for the chro-
matographic separation was a Hypersil GOLD PFP (50 × 3) (Thermo
Fisher Scientific, Franklin, MA). The sample was loaded into enrichment
columns using ultrapure water acidified at pH 4.5 with formic acid. After
the enrichment step, the analytes were transferred to the analytical col-
umn for their chromatographic separation. The gradient used is shown in
Table S2 (Supporting Information).
After separation, the detection of the selected analytes was accom-
plished by using a triple quadrupolemass spectrometer Thermo Scientific
TSQ Vantage (Thermo Fisher Scientific, San Jose, CA), equipped with a
Turbo Ion Spray source. All the analyses were performed operating in
the negative electrospray ionization (ESI (−)) mode. Acquisition was
performed in selected reactionmonitoringmode (SRM) to obtain enough
identification points (IP) for confirmation of each analyte (European
Commission Decision 2002/657/EC). The main m/z transitions are sum-
marized in Table S3 (Supporting Information). For analyte identification,
the following conditions had to be met: i) analyte retention time in the
sample must be in agreement with analyte retention time in the calibra-
tion curve; ii) two m/z transition were confirmed for every analyte;
iii) ratio between the two transitions in the sample compared to ratio
in the calibration curve should be in agreement to [calibration curve
average ± SD (calibration curve)]. Table S4 (Supporting Information)
provides the method limit of detection (MLOD) and the method limit
of quantification (MLOQ) of the selected compounds in the five ana-
lyzed human tissues.2.4. Quality assurance and quality control
To eliminate sources of contamination from the analytical system, all
the polytetrafluoroethylene (PTFE) tubing was replaced by polyether
ether ketone (PEEK) connections. In addition, an extra analytical column
(C8 50 × 3 Thermo Scientific) was directly placed upstream of the injec-
tor to trap the instrumental sources of analytes, and therefore, to mini-
mize the background signal and inter-run variability of all analytes.
Blanks, consisting on initial conditions of mobile phase, were analyzed
every 5 sample injections. For assessment of matrix interference in the
analysis, matrix-matched calibration curves, and blank samples, were
introduced in each run of analysis.
Spiking experiments were performed with blank animal (pig)
matrices of brain, lung, liver, bone and kidney fortified at three different
concentration levels (6, 12 and 24 ng/g of tissue). To assess the initial
concentrations of PFASs, these samples were analyzed prior to fortifica-
tion, being in all cases below the MLOD. The method was validated
according to the criteria described by the EC Decision 2002/657/EC.
The following parameters were established: instrumental selectivity
and methodology limits of detection and quantification (ILOD, MLOD,
ILOQ and MLOQ, respectively), linearity, recoveries, and precision
expressed as intraday and inter-day repeatability.2.5. Multivariate analysis
Before executing the multivariate data analysis, non-detected
values were assumed to be equal to one-half of the method limit of
detection (ND = 1/2 MLOD). The whole data set from the 5 human
tissues was analyzed both individually and by using a column-wise
99 × 20 matrix augmentation strategy (Navarro et al., 2006). Auto
scaling was chosen as pre-treatment method. With this procedure,
the mean of the column elements was subtracted from individual
elements and divided by their column standard deviation. Consequently,
each column has zero mean and unit variance (Brodnjak-Vončina et al.,
2002; Massart et al., 1998). Auto scaling can be applied either to the
individual matrices corresponding to each tissue before matrix augmen-
tation, or once they have been arranged in the column-wise augmented
datamatrix. The former system identifies differences in the tissues,while
the latter detects differences among individual samples.
Data were also subjected to Principal Component Analysis (PCA).
This is a data reduction technique aimed at explaining most of the
variance in the data by transforming a set of correlated measured var-
iables into a new set of uncorrelated Principal Components (PCs),
which preserve the relationships present in the original data (Rovira
et al., 2011a). The main goal of this multivariate statistical technique
is to extract useful information and provide an easier visualization of
the existent relationships between objects and variables determined
in large or complex data set (Rovira et al., 2011b). PCA can be easily
extended to the simultaneous analysis of multiple correlated data
sets. In the present study, PCA was conducted to assess the possible
distribution of the different compounds in the tissues studied, as
well as to assess any possible correlation between age and smoking
habits of the subjects and their PFASs accumulations. PCA modelling
was conducted using the PLS Toolbox (Eigenvector Research, Manson
WA, USA) appropriate functions under the MATLAB computer and
visualization environment (The Mathworks, Natick, MA, USA). Finally,
a hierarchical cluster analysis was conducted to confirm some of the
conclusions obtained by the PCA. Data were also treated by normaliza-
tion. The dissimilitudematrix was conducted by the Euclidean distance,
while the Ward method was chosen for the aggrupation approach.
This part of the multivariate analysis was conducted using the XLSTAT
module version 2012.042.
3. Results and discussion
The concentrations of detected PFASs in human samples of brain, liver,
lung, bone and kidney are depicted in Fig. 1. The complete set of results of
each one of the 99 analyzed samples is given in Table S5 (Supporting
Information), while a summary of median and range values is presented
in Table 1. All samples showed detectable values of at least two of the in-
vestigated compounds. Although PFASs accumulation followed different
trends depending on the specific tissue, some similarities were observed
between liver and brain, on one hand, and between kidney and lung, on
the other hand. In liver, PFHxA, PFOS and FHEA were the most prevalent
compounds, with median concentrations of 68.3, 41.9 and 16.7 ng/g, re-
spectively. PFOS, one of the most toxic PFASs, was present in 90% of the
samples, while PFOA could be quantified in 45% of the samples (median:
4.0 ng/g). In brain, PFHxA was the main compound, being detected in all
the samples at concentrations ranging from 10.1 to 486 ng/g. The contri-
butions of PFNA (median: 13.5 ng/g) and PFDA (median: 12.4 ng/g)were
also relatively important in brain samples. In contrast, PFOS was only
quantified in 20% of the samples (median: 1.9 ng/g), whereas PFOA was
not detected in anyof them. In general terms, lungwas the tissue showing
the highest accumulation of PFASs. PFBA and PHFxAwere the compounds
presenting the highestmedian concentrations (807 and207 ng/g, respec-
tively). Only two lung samples showed PFOS levels under the limit of
detection, with a median value of 28.4 ng/g. Although the percentage of
samples with detected values of PFOA fell down to 45%, the contribution





















































































































































































Fig. 1. Concentrations of various PFASs (in ng/g) in 5 human tissues from 20 residents of Tarragona (Catalonia, Spain).
357F. Pérez et al. / Environment International 59 (2013) 354–362other tissues and analytes. PFBA was also the predominant compound in
all kidney samples, whose median concentration was 263 ng/g. PFDoDA
and PFDA were also detected in kidney samples, but at much lower con-
centrations (median: 91.4 and 90.2 ng/g, respectively). High concentra-
tions of PFOS were also found in kidney (median: 55.0 ng/g), while the
presence of PFOA was minor. In contrast to lung, bone was identified as
the tissuewith the lowest burdens of PFASs. Furthermore, the PFASprofile
was substantially different from those of the remaining tissues, as PFOA
was, far the major contributor to the total concentration of PFASs
(median: 20.9 ng/g). In turn, PFOS was not detected in any of the bone
samples (Table 1). In summary, the profiles of PFASs accumulation in
the different tissues reflected some common trends. Thus, PFHxA showed
the highest concentrations in brain and liver, while PFBA presented the
maximummedian levels in kidney and lung, with PFOA as the predomi-
nant compound in bone. PFOS accumulated basically in lung, liver and
kidney, while the levels of PFOS in bone and brain were very low.We hy-
pothesized that since PFBA is a short chain compound, its predominance
in lung could reflect the inhalation of contaminated dust and the industri-
al replacement of the eight carbons chain compounds by shorter ones. In
addition, the human half-life of this compound is much shorter (3 days)
(Chang et al., 2008) compared to the half-life to other longer chain com-
pounds as those with 8 carbon-chain thereby accounting for its detection
in other tissues as kidney. As aforementioned, there is an important lack
of studies reporting PFASs levels in human tissues, excepting plasma.
In comparison to previous results (Kärrman et al., 2009; Maestri et al.,
2006; Olsen et al., 2003), the current concentrations of PFOS in liverfrom residents in Tarragona fall in the higher part of the range. However,
this comparison can be only taken into account as a first indication.
The physical–chemical properties of each chemical are responsible
for their tissue-specific accumulation profiles. However, the overall
body burden can be similar although the chemicals accumulate in differ-
ent tissues. In order to determinewhether exposure to PFASs is related to
exposures to other contaminants, the levels of PFASs in each sample
were evaluated to determinewhether they correlatewith the concentra-
tions of somemetals and PCDD/Fs. The content of arsenic (As), cadmium
(Cd), chromium (Cr), mercury (Hg), manganese (Mn), nickel (Ni), lead
(Pb), tin (Sn), and thallium (Tl) had been previously determined in the
same human tissue samples (unpublished results). With a few excep-
tions, the levels of PFASswere not associatedwith those ofmost trace el-
ements. However, a significant Pearson correlation was noted between
PFOA and As (p b 0.001), as well as between PFOA and Pb (p b 0.001).
Manganese was the element presenting a significant correlation with a
higher number of PFASs: PFDS, PFUDA, and PFTeDA (p b 0.001 in all
cases). Finally, Ni correlatedwith PFHxDA. However, PFOS did not corre-
late with any of the above elements (Table S6; Supporting Information).
The concentrations of PCDD/Fs had been also analyzed in adipose tissues
from15 of the same20 individuals (Nadal et al., 2009). ThemeanPCDD/F
concentration in adipose tissue was 14.6 pg WHO-TEQ/g of fat (range:
3.3–55.4 pg WHO-TEQ/g of fat). The total levels of PCDD/Fs, as well as
those of the 17 2,3,7,8-chlorinated congeners, were compared with the
concentrations of PFASs accumulated in the 5 human tissues here ana-






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































358 F. Pérez et al. / Environment International 59 (2013) 354–362observed between the total sum of PCDD/Fs and the total amount of
PFASs (Table S7; Supporting Information). It is well known that the
toxicity of dioxins is mediated through the activation of the Aryl hydro-
carbon Receptor (AhR) (White and Birnbaum, 2009). In contrast, the
mode-of-action (MoA) for PFOA as well as other PFASs, is not so well
understood (Post et al., 2012). Notwithstanding, it must be noted that
data on PCDD/Fs were only available for adipose tissue, while PFASs
levels refer to another 5 different tissues (liver, brain, kidney, bone, and
lung). Therefore, these data are not entirely comparable, and conse-
quently, this indication cannot be confirmed.
The pharmacokinetic properties of PFOA and PFOS are well studied
(Loccisano et al., 2012). These parameters have been used in the devel-
opment of pharmacokinetic models, aimed at describing the human
distribution of PFOA and PFOS (Loccisano et al., 2011; Thompson
et al., 2010), among other PFASs. Physiologically based pharmacokinetic
(PBPK) models are mathematical representations of the human body,
where organs are considered as compartments (Fàbrega et al., 2011).
The overall goal of developing these PBPK models is to extrapolate to
humans the distribution of chemicals in the body, in order to enhance
the scientific basis for human health risk assessment of PFASs
(Loccisano et al., 2012). According to the results of studies with experi-
mental animals, these compounds are well absorbed orally (Loccisano
et al., 2012). Therefore, ingestion should be considered a key pathway.
A clear relationship between the intake of PFOA, basically through
drinking water consumption, and serum concentrations in humans,
has been found (Emmett et al., 2006), with a with a serum:drinking
water ratio of about 100:1 (Post et al., 2012). Although a number of
PBPK models have been described, most of them have been based
only on animal data, while human data are still very scarce. To the
best of our knowledge, we here report, for the very first time, the simul-
taneous accumulation of PFASs in various human tissues. This informa-
tion should be beneficial for the development of theoretical PBPK
models, whose validation is still incomplete. Consequently, forensic
analyses offer a practical way to explore the real accumulation of
those pollutants in the human body.
In the current study, PCA analysis was used to determine the varia-
tion of PFASs accumulation between tissues, as well as to extract possi-
ble relations between the individual concentrations and other factors,
such as age and smoking. The PCA results are summarized in Table 2.
The first PC explained a variance ranging between 12% and 29% of the
total variance, for all the different tissues analyzed, while PC2 and PC3
variances ranged 19–20% and 8–15% respectively. The percentage of
explained variance for those PCAs performed in the individual tissues
was always higher than that in the augmented matrices. The explained
variances differed in the two groups of PCAs. In the augmented matri-
ces, they increased very slowly, not reaching 50% of the total variance
until PC6. This indicates the presence of multiple independent distribu-
tion processes of PFASs in the considered tissues. On the other hand,
in the individual PCAs of each tissue, the variance increased faster,
reaching 50% of the total variance in the PC3 in most of the cases, indi-
cating similar distribution processes when the same tissue is consid-
ered. Fig. 2 depicts the loadings plot for the first two PCs of the
augmented and auto scaled data matrices. The first PC had positive
loadings for all acidic compounds, from low to high contributions
depending on the compound, except for PFHxA, PFHpA, with moderate
negative loadings, and PFDOA, with a high negative loading. In this first
PC, perfluoroalkyl sulphonates presented positive loadings, with higher
contributions of PFHxS and PFDS. Regarding telomer acids (FHEA, FDEA
and FOEA), the three compounds showedmoderate loadings, negative-
ly for FHEA and FDEA, and positively for FOEA. The second PC showed
positive loadings for most acidic compounds except for PFNA, PFDA,
PFUdA and PFTeDA, with especially high contributions of PFBA, PFOA,
PFDA and PFTrDA. Perfluoroalkyl sulphonates presented moderate
contributions to the second PC, being positive for PFBS and PFDS, and
negative for the remaining two. The telomer acids presented positive
loadings for FOEA and FDEA, and negative for FHEA. When plotting
Table 2
Percentages of explained variances obtained by PCAs applied to Allaug-auto, Allauto-aug
and the individual matrices of the 5 tissues.
Matrix Allaug-auto Allauto-aug Liver Brain Bone Lung Kidney





















































































In parenthesis, percentage of accumulated variance for that particular component.
Allaug-auto: augmented matrix of the 5 individual tissues and then autoscaled.
Allauto-aug: individually autoscaled matrixes of the 5 tissues and then augmented.
359F. Pérez et al. / Environment International 59 (2013) 354–362the scores using these two PCs, the samples can be grouped into each
one of the 5 tissues analyzed (Fig. 3). This means that the profile of
PFASs found in each tissue is different from the others. Thus, PC1
allowed the separation between lungs, kidney and brain, with positive
contribution, while bone and liver showed a negative contribution. In
turn, PC2 reflected a separation between lung and bone, with positive
loadings, and the remaining three tissues, with negative loadings.
When considering the remaining PCs, the behavior was similar.
Fig. S1 (Supporting Information) depicts the loadings plot for the
first PC of each PCA performed in the individual matrices of each
tissue. In liver, the first PC showed high positive loadings for acidic com-








































Fig. 2. Loadings of the first two principal components (PFTrDA). In kidney, a similar profile was obtained, with acidic PFASs
with an odd number of carbon chain (PFPeA, PFNA, PFUdA and PFTrDA)
acting as prevalent compounds. In brain, acidic compounds with a pair
number of carbon chain (PFBA and PFHxA) and sulphonates (PFBS,
PFOS and PFDS) were the predominant compounds. Unlike other
PFASs, sulphonates also showed a high contribution in bone. Lung sam-
ples also presented positive loadings for most acidic compounds with a
pair number of carbon chain (PFBA, PFHxA, PFOA, PFDoA), as well as
some of the sulphonates (PFOS, PFDS) and FOEA. This different profile
of PC1 confirms the different distribution pattern of PFASs according
to each specific tissue. The influence of smoking in the accumulation
of PFAs in the lungs was also studied. As shown in Fig. 4, smoker sub-
jects presented lower contributions of PC1 and PC2 than non-smokers.
It means less accumulation of the PFASs, which contribute to these
PCs. When considering the rest of PCs, a similar behavior is observed.
Considering the samples included in this study, a negative correlation
between smoking habits and accumulations of PFAs in lung is observed.
Further investigation with a higher number of subjects should be
performed to check this relationship.
The accumulation of PFASs with age was studied in the analyzed tis-
sues. In general terms, older people (more than 60 years) showed
higher concentrations of PFASs, which is a clear indication that these
compounds accumulate after a long-term exposure. All middle-age
(40–60 years) individuals presented fairly similar levels of PFASs in
the different tissues. However, some young subjects (18–39 years)
also showed relatively high levels of PFASs. These values could be due
to differential accumulation factors, such as dietary intake, living habits,
and/or early exposure. This was also confirmed after performing a hier-
archical classification (Fig. S2). Finally, a special correlation between
smoking habits and PFAS accumulation in lung was performed.
Although PCs did not show a positive relation between bothPFTeDA PFHxDA PFDOA PFBS PFHxS PFOS PFDS FHEA FOEA FDEA
PFTeDA PFHxDA PFDOA PFBS PFHxS PFOS PFDS FHEA FOEA FDEA
PCs) for the augmented and auto scaled matrices.















































































































Fig. 3. Scores plots for the first two principal components (PCs) for the augmented and autoscaled matrix.










































Fig. 4. Principal Component Analysis (PCA) of PFASs in lung samples.
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361F. Pérez et al. / Environment International 59 (2013) 354–362parameters, the current number of samples was not sufficient to estab-
lish conclusions on this issue. Further investigations involving a higher
number of subjects are necessary.
4. Conclusions
In this study, an effective analytical method optimized for the
ultra-trace analysis of 21 PFASs in human tissues, using both small
sample sizes (amount: 1 g) and a reduced sample manipulation,
was addressed. The application of this approach to the analysis of
99 samples of five different tissues from 20 subjects demonstrated,
for the very first time, the accumulation of certain short chain com-
pounds, such as PFBA and PFHxA, in human tissues. Moreover, the
results from the chemical analysis, together with the application of
multivariate statistical techniques, showed a different accumulation
pattern of the analyzed compounds in human tissues. Only few corre-
lations were noted in the concentrations of metals and those of PFASs.
However, interestingly, certain negative association between the con-
tents of PFASs in those 5 autopsy tissues, and the levels of PCDD/Fs in
adipose tissue, was observed. This finding suggests the need to fully
characterize the toxicity mechanisms of PFASs, which are not currently
so well understood as those of PCDD/Fs. Notwithstanding, as data refer
to different biological compartments, values are not entirely compara-
ble. In any case, the current results should be of importance for the
validation of PBPK models, which are being developed for humans.
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